# Utah Medical Products share price today (Utah Medical Products, Inc., UTMD)

> Utah Medical Products, Inc.'s share price has risen faster than its earnings: +20.5% in a year, against −12.1% for earnings per share. UTMD · Healthcare · Medical Instruments & Supplies · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/utmd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting worse, from the last 12 quarters
- Price: $70.02 (+20.5% in a year)
- P/E: 21.0× (higher than 76% of the last 1 year)
- Revenue (Sep 2026): $8.6 M (−12.1% on a year ago)
- Profit (Sep 2026): $2.8 M (+5.9% on a year ago)
- Operating margin: 34.8% (+4.2 points on a year ago)
- ROE: 10%, FY25
- ROIC: 26.9%, against a 6.4% cost of capital: +20.5 points

The main question: the share price moved +20.5% in a year while yearly earnings per share moved −12.1%. The difference came from the market paying a higher multiple. ## What is the Utah Medical Products share price today? Utah Medical Products, Inc.'s share price was $70.02 at the close on 3 November 2026. That is 2.7% above its average price over the last 200 trading days. In the last 52 weeks it traded between $55 and $75, and at that close it sat 77% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 1 week in a row. Over the last 1 year the share price moved +24% while the S&P 500 moved +21%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Utah Medical Products pay? Utah Medical Products, Inc. paid $1.24 per share over the last four reported quarters. The most recent declaration was $0.31 for Jun 2026. At today's price of $70.02 that is a yield of 1.77%, based on dividends already paid, not a forecast. ## Which stock lists is Utah Medical Products on? Utah Medical Products is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Utah Medical Products profitable? Utah Medical Products, Inc. earned $2.8 M of net profit in the Sep 2026 quarter, +5.9% on the same quarter a year earlier. Full-year FY25 profit was $11.3 M. Over 4 years profit has grown −6.5% a year on average. That is 32.3% of the quarter's revenue. The same quarter a year earlier earned $2.6 M. For the full year, FY25 profit was $11.3 M (−18.7% on the year before). Why profit moved: revenue changed −12.1% on a year earlier and the margin moved +4.2 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed −8.0% and revenue −9.4%. Profit and revenue are moving at about the same pace. ## How much revenue does Utah Medical Products make, and is it growing? Utah Medical Products, Inc. reported $8.6 M of revenue in the Sep 2026 quarter, −12.1% on the same quarter a year earlier. Over 4 years it has grown −5.9% a year on average. The last full year, FY25, came in at $38.5 M. The last four reported quarters add to $34.9 M. FY25 revenue was $38.5 M, −5.8% on the year before. Recent pace: the last four quarters grew −9.4% on average, against −5.9% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −9.6%, against −11.0% a year over the last 8 quarters (stabilising); profit over the last 12 months grew −8.4%, against −16.5% a year (accelerating). ## How much of every $100 of sales does Utah Medical Products keep? Utah Medical Products, Inc.'s operating margin was 34.8% in the Sep 2026 quarter, 4.2 percentage points higher than the same quarter a year ago. Across 5 years it has been between 33.1% and 38.5%. The latest quarter is within that range. Why the margin moved: operating margin changed +4.2 percentage points on the year while gross margin changed −1.0 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Utah Medical Products' profit turning into cash? Over the last 3 years, 124% of Utah Medical Products, Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $14.7 M of operating cash against $11.3 M of profit. After $371 K of spending on assets, $14.3 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Utah Medical Products' cash go? Utah Medical Products, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $1.2 M on assets over the last 3 years. Averaged over those years that is 1.1% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $1.2 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Utah Medical Products' P/E ratio, and how does it compare with its own history? Utah Medical Products, Inc.'s P/E is 21.0×, near the high end of its own history: higher than 76% of past readings. Its usual P/E (the middle reading) is 18.6×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −12.1% while the price moved +20.5%. The price did better than earnings, which pushed the multiple up within its own range. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Utah Medical Products business getting better or worse? Utah Medical Products, Inc.'s business is getting worse. Revenue, profit and EPS growth are shrinking: revenue growth is −9.6% in the latest quarter, against −3.9% at its best in 12 quarters, with ROCE steady at 9.9%. This is based on 12 quarters of 4 measures. Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind. ## How much does Utah Medical Products earn on its capital? Utah Medical Products, Inc. earned a ROE of 10% in FY25. Its return on capital used (ROIC) is 20.5 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 29.3% net margin and 0.31× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 29.3% net margin × 0.31× asset turnover × 1.03× leverage (assets divided by equity) ≈ 9.4% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 26.9% − 6.4% = +20.5 percentage points. The 6.4% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. The 26.9% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 29.8%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Utah Medical Products have too much debt? Utah Medical Products, Inc. has total debt of $180 K against shareholder equity of $123 M as of Sep 2026, so its debt is 0.00× its equity, which is very little. Year by year, that ratio went from 0.00 in FY21 to 0.00 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Utah Medical Products shareholding pattern? 5.1% of Utah Medical Products, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 3.8 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Utah Medical Products from balance-sheet trouble? For Utah Medical Products, Inc., the Z-score is 49.60. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 49.60 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Utah Medical Products rank in its industry? There is no score against its industry: Utah Medical Products, Inc. is not among the largest members shown in this industry comparison for Medical Instruments & Supplies. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Utah Medical Products compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Utah Medical Products in size? Utah Medical Products is the 36th largest of 38 Medical Instruments & Supplies companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: AngioDynamics, Inc., Embecta Corp., Sanara MedTech Inc. and OraSure Technologies, Inc. Just below it: Pro-Dex, Inc. and Anbio Biotechnology. ### Medical Instruments & Supplies companies close in size

1. [AngioDynamics, Inc.](https://www.sectoralpha.in/us/stocks/ango) $493 million
2. [Embecta Corp.](https://www.sectoralpha.in/us/stocks/embc) $344 million
3. [Sanara MedTech Inc.](https://www.sectoralpha.in/us/stocks/smti) $296 million
4. [OraSure Technologies, Inc.](https://www.sectoralpha.in/us/stocks/osur) $243 million
5. Utah Medical Products, Inc. $222 million
6. [Pro-Dex, Inc.](https://www.sectoralpha.in/us/stocks/pdex) $193 million
7. [Anbio Biotechnology](https://www.sectoralpha.in/us/stocks/nnnn) $157 million

[All 38 Medical Instruments & Supplies companies, largest first](https://www.sectoralpha.in/us/sectors/medical-instruments-supplies#all-companies)

### Companies close in size in other industries

1. [RCI Hospitality Holdings, Inc.](https://www.sectoralpha.in/us/stocks/rick) $216 million · Restaurants
2. [Obook Holdings Inc.](https://www.sectoralpha.in/us/stocks/owls) $216 million · Software - Infrastructure
3. Utah Medical Products, Inc. $216 million
4. [MaxsMaking Inc.](https://www.sectoralpha.in/us/stocks/mamk) $216 million · Conglomerates
5. [Nature's Sunshine Products, Inc.](https://www.sectoralpha.in/us/stocks/natr) $216 million · Packaged Foods

## What else do people ask about Utah Medical Products? ### What were Utah Medical Products's latest quarterly results? Utah Medical Products, Inc. reported revenue of $8.6 M and net profit of $2.8 M for the Sep 2026 quarter. Revenue fell 12.1% and profit rose 5.9% compared with a year earlier. Earnings per share were $0.88. The operating margin was 34.8%, 4.2 percentage points higher than a year earlier (as of 3 November 2026). ### What is Utah Medical Products's market cap? Utah Medical Products, Inc.'s market capitalisation is $222 M at a stock price of $70.02. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Utah Medical Products performing? Utah Medical Products, Inc.'s latest readings are below. In its latest quarter, revenue fell 12.1% and profit rose 5.9% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 1 week running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Utah Medical Products's stock price go up? This page does not forecast Utah Medical Products, Inc.'s stock price. What it shows instead: the stock price is $70.02. Its P/E of 21.0× is higher than 76% of its own last 1 years. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Utah Medical Products in its business cycle? Utah Medical Products, Inc.'s FY25 operating margin was 33.1%, against a 5-year range of 33.1% to 38.5%: the low end of its own range, which is often where recoveries start. The latest quarter was 34.8%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Utah Medical Products story? The main question: the share price moved +20.5% in a year while yearly earnings per share moved −12.1%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Utah Medical Products a stock worth studying right now? What the numbers show: Utah Medical Products, Inc.'s share price has risen faster than its earnings: +20.5% in a year, against −12.1% for earnings per share. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.